Stock CL CRESCO LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cresco Labs Inc.

Equities

CL

CA22587M1068

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 03:59:47 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.82 CAD +6.02% Intraday chart for Cresco Labs Inc. +2.55% +57.54%
Apr. 15 Jushi Holdings Inc. Brief: Appointed Todd West as Chief Operating Officer, Effective April 12, 2024; Most Recent Role Was As Executive Vice President of Operations at Cresco Labs Inc MT
Mar. 13 Cresco Labs Swings to Profit in Q4, Revenue Drops; Up 10.4% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 940.1 2,343 1,929 545.3 459.7 716.3 - -
Enterprise Value (EV) 1 891 2,391 2,191 1,094 1,034 1,148 1,167 716.3
P/E ratio -18.6 x -25.3 x -5.44 x -2.54 x -2.5 x -30.8 x -29.1 x 18.7 x
Yield - - - - - - - -
Capitalization / Revenue 7.31 x 4.92 x 2.35 x 0.65 x 0.6 x 0.96 x 0.9 x 0.83 x
EV / Revenue 6.93 x 5.02 x 2.67 x 1.3 x 1.34 x 1.54 x 1.47 x 0.83 x
EV / EBITDA 112 x 20.6 x 11.3 x 6.3 x 5.95 x 5.89 x 5.69 x 3.22 x
EV / FCF -7.62 x -26.8 x -27.6 x -17 x 325 x 38.9 x 32.3 x -358 x
FCF Yield -13.1% -3.73% -3.62% -5.88% 0.31% 2.57% 3.1% -0.28%
Price to Book - - - 0.92 x 1.02 x 1.65 x 1.82 x 2.04 x
Nbr of stocks (in thousands) 136,840 237,757 290,734 301,783 340,470 347,734 - -
Reference price 2 6.870 9.853 6.636 1.807 1.350 2.060 2.060 2.060
Announcement Date 4/27/20 3/25/21 3/23/22 3/16/23 3/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 128.5 476.3 821.7 842.7 770.9 744.2 793 867.8
EBITDA 1 7.989 116 194 173.6 173.6 194.8 205.2 222.2
EBIT 1 -34.26 55.84 -217.4 -83.39 -87.82 106.4 119.3 158.8
Operating Margin -26.65% 11.73% -26.45% -9.9% -11.39% 14.29% 15.04% 18.3%
Earnings before Tax (EBT) 1 -50.84 7.158 -256.7 -126 -146.9 51.27 65.88 133.6
Net income 1 -43.2 -81.92 -296.8 -215.1 -175.5 -30.29 -38.79 97.2
Net margin -33.61% -17.2% -36.13% -25.53% -22.77% -4.07% -4.89% 11.2%
EPS 2 -0.3700 -0.3900 -1.220 -0.7100 -0.5400 -0.0669 -0.0708 0.1100
Free Cash Flow 1 -116.9 -89.1 -79.39 -64.28 3.179 29.53 36.13 -2
FCF margin -90.92% -18.71% -9.66% -7.63% 0.41% 3.97% 4.56% -0.23%
FCF Conversion (EBITDA) - - - - 1.83% 15.15% 17.6% -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 4/27/20 3/25/21 3/23/22 3/16/23 3/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 215.5 217.8 214.4 218.2 210.5 199.6 194.2 197.9 190.6 188.2 183.2 184.3 185 191.6 190.2
EBITDA 1 56.45 56.99 50.75 50.59 41.74 30.53 29.28 40.48 49.05 54.83 47.44 48.45 48.81 50.94 47.3
EBIT 1 -264 15.56 20.27 22.68 16.24 -142.6 3.586 -10.75 -107.8 27.1 25.38 26.71 27.47 29.88 30.67
Operating Margin -122.52% 7.14% 9.45% 10.39% 7.72% -71.44% 1.85% -5.43% -56.55% 14.4% 13.86% 14.49% 14.85% 15.6% 16.12%
Earnings before Tax (EBT) 1 -275.9 11.62 -0.868 15.34 15.48 -156 -11 -29.53 -119.2 12.82 10.93 12.17 12.92 15.27 15.51
Net income 1 -270.6 -11.91 -23.68 -8.296 -3.249 -179.9 -27.81 -43.46 -113.4 2.635 -9.213 -8.217 -7.907 -6.02 -8.446
Net margin -125.6% -5.47% -11.04% -3.8% -1.54% -90.13% -14.32% -21.96% -59.53% 1.4% -5.03% -4.46% -4.27% -3.14% -4.44%
EPS 2 -1.000 -0.0300 -0.0900 -0.0500 -0.0300 -0.5400 -0.0913 -0.1200 -0.3400 0.0200 -0.0207 -0.0193 -0.0164 -0.0124 -0.0200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/11/21 3/23/22 5/18/22 8/17/22 11/15/22 3/16/23 5/24/23 8/16/23 11/15/23 3/13/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 48.2 261 549 574 432 451 -
Net Cash position 1 49.1 - - - - - - -
Leverage (Debt/EBITDA) - 0.4153 x 1.348 x 3.16 x 3.307 x 2.216 x 2.197 x -
Free Cash Flow 1 -117 -89.1 -79.4 -64.3 3.18 29.5 36.1 -2
ROE (net income / shareholders' equity) -7.48% -13.8% 2.23% -6.99% -35.4% -6.8% - -
ROA (Net income/ Total Assets) -11.5% -5.39% 0.91% -2.88% -12.2% -2.1% -1.4% -
Assets 1 374.1 1,519 -32,626 7,467 1,436 1,442 2,771 -
Book Value Per Share 2 - - - 1.970 1.320 1.250 1.130 1.010
Cash Flow per Share 2 -0.2100 -0.0500 - - 0.1800 0.2400 0.2500 -
Capex 1 91.7 78.3 93.9 83 55.4 54.3 38.2 20
Capex / Sales 71.32% 16.44% 11.42% 9.85% 7.18% 7.29% 4.81% 2.3%
Announcement Date 4/27/20 3/25/21 3/23/22 3/16/23 3/13/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Cresco Labs Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
2.06 USD
Average target price
4.363 USD
Spread / Average Target
+111.77%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CRESCO LABS INC. Stock Cresco Labs Inc.
+57.54% 716M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CL Stock
  4. Financials Cresco Labs Inc.